|
|
|
Company Name
|
Astellas Pharma Inc.
|
|
Drug Name
|
Mirabegron (NDA)
|
|
Event Name
|
FDA decision on Mirabegron for proposed treatment of overactive bladder
|
|
Event Date
|
06/29/2012
|
|
Outcome
|
FDA approved Myrbetriq (mirabegron) for treatment of overactive bladder on June 28
|
|
Drug Status
|
|
|
Rival Drugs
|
|
|
Market Potential
|
|
|
Other Approvals
|
|
|
News |
|
|
|
Return to FDA Calendar
|